← All organizations
First clinical trial
Jan 1, 1998First marketed drug
Sep 20, 1995First NDA
Sep 20, 1995Last known activity
Feb 1, 2003
Acquired by GlaxoSmithKline on Jan 1, 2000
Timeline
1990s
- Jan 1, 1995
Glaxo Wellcome— Founded
- Jan 1, 1995
Burroughs Wellcome— Acquired
- Jan 1, 1995
Glaxo— Acquired
2000s
- Jan 1, 2000
GlaxoSmithKline— Acquired By
- Feb 11, 2000
alosetron— NDA Organization
Drugs by trial phase (60 distinct, 142 trials)
Phase 4 (11 own, 2 via acquisition)
Phase 3 (13 own, 5 via acquisition)
Phase 2 (14 own, 1 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- AIDS Dementia Complex
- Bacterial Infections
- Chickenpox
- Colorectal Neoplasms
- Communicable Diseases
- Cytomegalovirus Infections
- Dementia
- Disease Susceptibility
- Herpes Genitalis
- Herpes Simplex
- Herpes Zoster
- HIV Infections
- Infections
- Lipodystrophy
- Neurologic Manifestations
- Pneumonia
- Pneumonia, Pneumocystis
- Seizures
- Sinusitis
- Toxoplasmosis
- Toxoplasmosis, Cerebral
Marketed drugs (7)
Subsidiaries (2 direct, 4 total across the full acquisition tree)
Recent trials (50)
- NCT00006441CollaboratorN/AFeb 1, 2003
- NCT00002234CollaboratorPhase 2Aug 30, 2001
- NCT00006617CollaboratorN/ADec 6, 2000
- NCT00009061Lead sponsorPhase 3Nov 1, 2000
- NCT00008554Lead sponsorPhase 3Nov 1, 2000
- NCT00005764Lead sponsorPhase 4May 1, 2000
- NCT00005017Lead sponsorPhase 4Apr 3, 2000
- NCT00004981Lead sponsorPhase 3Mar 13, 2000
- NCT00001991Lead sponsorN/ANov 2, 1999
- NCT00002200Lead sponsorN/ANov 2, 1999
- NCT00001054CollaboratorPhase 1Nov 2, 1999
- NCT00002335Lead sponsorPhase 1Nov 2, 1999
- NCT00002213Lead sponsorPhase 2Nov 2, 1999
- NCT00002364Lead sponsorPhase 2Nov 2, 1999
- NCT00001007CollaboratorPhase 1Nov 2, 1999
Details
- Founded
- London, GB Jan 1, 1995
- First NDA
- Sep 20, 1995
- Last known activity
- Feb 1, 2003
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval